ICANOMAB
IcanoMAB is a private Biotech company focusing on the pre-clinical and development of precision canonical antibodies for the treatment of cancer, immune-system related diseases, and Covid-19. The company is developing its proprietary clinical candidates to exploit novel approaches improving clinical outcomes in immuno-oncology, solid tumors and immunology, and inflammation.
ICANOMAB
Industry:
Biotechnology Clinical Trials Health Care Medical
Address:
Polling, Bayern, Germany
Country:
Germany
Website Url:
http://www.icanomab.com
Status:
Active
Contact:
+49 881 399 08940
Technology used in webpage:
SPF SSL By Default WordPress Apache Wordpress Plugins Microsoft Exchange Online Office 365 Mail IPv6 PHP PHP 7
Official Site Inspections
http://www.icanomab.com
- Host name: 217-160-0-172.elastic-ssl.ui-r.com
- IP address: 217.160.0.172
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "IcanoMAB"
Antibody Diversity and Precision Signaling matters
IcanoMAB is a private Biotech company headquartered in Polling, Germany focusing on the pre-clinical and development of precision canonical antibodies for the treatment of cancer, immune-system- and inflammation-related-diseases …See details»
IcanoMAB - Crunchbase Company Profile & Funding
IcanoMAB is a private Biotech company focusing on the pre-clinical and development of precision canonical antibodies for the treatment of cancer, immune-system related diseases, and Covid …See details»
IcanoMab GmbH - Life-Sciences-Europe.com
May 8, 2020 IcanoMAB is a private Biotech company focusing on the pre-clinical and development of precision canonical antibodies for the treatment of cancer, immune-system …See details»
A German Biotech Company Developing Novel …
Sep 10, 2020 Its latest addition is a recently founded German-based IcanoMAB, a privately-funded biotech company specializing in pre-clinical and clinical development of novel MABs for several diseases, including COVID-19 [2]. The …See details»
IcanoMAB GmbH founded with private funding to develop …
IcanoMAB GmbH Tassilostr. 2, 82398 Polling, Germany +49 881 39 90 89 40 [email protected] About IcanoMAB IcanoMAB is a private Biotech company focusing on …See details»
IcanoMAB - VentureRadar
IcanoMAB is developing canonical signaling monoclonal antibodies to significantly improve therapeutic treatments in Oncology, Immune-modulation, Immunology and Covid-19. Founded …See details»
IcanoMAB - Crunchbase
IcanoMAB is a biotech company focusing on pre-clinical and clinical development for the treatment of cancer and other related diseases. Search Crunchbase. Start Free Trial . Chrome …See details»
IcanoMAB GmbH Founded with Private Funding to Develop …
Sep 8, 2020 IcanoMAB is a private Biotech company focusing on the pre-clinical and development of precision canonical antibodies for the treatment of cancer, immune-system …See details»
IcanoMAB - Tech Stack, Apps, Patents & Trademarks - Crunchbase
IcanoMAB is a biotech company focusing on pre-clinical and clinical development for the treatment of cancer and other related diseases. Search Crunchbase. Start Free Trial . Chrome …See details»
IcanoMAB announces a novel IL-18 signaling blocker (anti-IL-1R7) …
IcanoMAB GmbH Tassilostr. 2, 82398 Polling, Germany +49 881 39 90 89 40 [email protected] About IcanoMAB IcanoMAB is a private Biotech company focusing on …See details»
IcanoMAB GmbH Founded with Private Funding to Develop …
POLLING, Germany, September 07, 2020 /B3C newswire/ --IcanoMAB, a privately-funded biotech company focusing on the pre-clinical and clinical development of novel precision canonical …See details»
IcanoMAB GmbH Founded with Private Funding to Develop …
Sep 7, 2020 Addressing those needs, IcanoMAB’s clinical lead candidates have been developed to date and are in collaborations with leading experts and renowned organizations across the …See details»
IcanoMAB Announces a Novel IL-18 Signaling Blocker
May 20, 2021 IcanoMAB, a privately-funded biotech company focusing on the pre-clinical and clinical development of novel precision antibodies for the treatment of cancer, immune-system …See details»
IcanoMAB GmbH Founded with Private Funding to Develop Precis
IcanoMAB, a privately-funded biotech company focusing on the pre-clinical and clinical development of novel precision canonical antibodies for the treatment of cancer, immune …See details»
CD40 agonist (Icanomab) - Drug Targets, Indications, Patents
Literatures (Medical) associated with CD40 agonist (Icanomab) 01 Dec 2024 · Biomaterials CD40 agonist engineered immunosomes modulated tumor microenvironment and showed pro …See details»
CD40-antigen-stimulant - IcanoMAB - AdisInsight - Springer
IcanoMAB is developing a precision canonical antibody, activating CD40-antigen for the treatment of solid tumours and infectious diseases. The activation of ... If your organization has a …See details»
IcanoMAB Announces a Novel IL-18 Signaling Blocker (anti-IL …
May 19, 2021 IcanoMAB is a private Biotech company focusing on the pre-clinical and development of precision canonical antibodies for the treatment of cancer, immune-system …See details»
IL-1R7 antagonist - IcanoMAB - AdisInsight - Springer
IL-1R7 antagonist - IcanoMAB Latest Information Update: 28 Oct 2024. Price : $50 * Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and …See details»
IcanoMAB Announces a Novel IL-18 Signaling Blocker Treatment …
IcanoMAB’s scientific approach, pre-clinical evidence and development plan were supported as presented. Systemic inflammation can result in severe pathologies with high mortality. The …See details»
HER2newC apoptosis inducer - IcanoMAB - AdisInsight - Springer
IcanoMAB is developing a HER2newC apoptosis inducing monoclonal antibody for the treatment of breast cancer. The precision canonical antibody demonstrates a ... If your organization has …See details»